NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT04187352,A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma,https://clinicaltrials.gov/study/NCT04187352,,COMPLETED,"Phase III Study to Investigate the Efficacy and Safety of CS1001 or Placebo in Combination with FP as First-Line Therapy in Subjects with Unresectable Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma",NO,"Unresectable Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma",DRUG: CS1001+ Fluorouracil+Cisplatin|DRUG: Placebo+ Fluorouracil+Cisplatin,"Progression-free survival (PFS) assessed by Blinded Independent Central Review (BICR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, PFS was defined as the time from randomization to the first documented progressive disease (PD) per RECIST 1.1 as assessed by BICR, or death due to any cause, whichever occurred first., Approximately 43 months from the time of randomization|Overall survival (OS), OS was defined as the time from randomization to death due to any cause., Approximately 43 months from the time of randomization","PFS assessed by investigators according to RECIST v1.1, PFS was defined as the time from randomization to the first documented progressive disease (PD) per RECIST 1.1 as assessed by investigators, or death due to any cause, whichever occurred first., Approximately 43 months from the time of randomization|Objective response rate (ORR) assessed by BICR and investigators according to RECIST v1.1, ORR was defined as the percentage of participants in the analysis population who had a Complete Response (CR) or a Partial Response (PR) per RECIST 1.1., Approximately 43 months from the time of randomization|Duration of response (DoR) assessed by BICR and investigators according to RECIST v1.1, DOR was defined as the time from first documented evidence of confirmed CR or PR until PD or death due to any cause, whichever occurred first., Approximately 43 months from the time of randomization",,CStone Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE3,540,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",CS1001-304,2019-12-19,2022-10-07,2022-10-07,2019-12-05,,2023-11-24,"The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China|Anhui Provincial Hospital, Hefei, Anhui, China|Hefei Second People's Hospital, Hefei, Anhui, China|The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China|The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China|Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China|Beijing Tsinghua Changgung Hospital, Beijing, Beijing, China|Peaking University International Hospital, Beijing, Beijing, China|Chongqing General Hospital, Chongqing, Chongqing, China|Special Medical Center of The People's Liberation Army of China, Chongqing, Chongqing, China|The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China|Fujian Cancer Hospital, Fuzhou, Fujian, China|The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China|The First People's Hospital of Foshan, Foshan, Guangdong, China|Cancer Center of Guangzhou Medical University, Guangzhou, Guangdong, China|Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, Guangdong, China|Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China|Jiangmen Central Hospital, Jiangmen, Guangdong, China|Jieyang People's Hospital, Jieyang, Guangdong, China|Affiliated Tumor Hospital of Shantou University Medical College, Shantou, Guangdong, China|The Fifth Affiliated Hospital of Sun Yat sen University, Zhuhai, Guangdong, China|Guangxi Medical University Affiliated Tumor Hospital, Nanning, Guangxi, China|Hainan General Hospital, Haikou, Hainan, China|The Second Affiliated Hospital of Hainan Medical University, Haikou, Hainan, China|Affiliated Hospital of Chengde Medical University, Chengde, Hebei, China|Handan Central Hospital, Handan, Hebei, China|Shijiazhuang People's Hospital, Shijiazhuang, Hebei, China|The Affiliated Tumor Hospital of Harbin Meidical University, Haerbin, Heilongjiang, China|Anyang Cancer Hospital, Anyang, Henan, China|The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China|Nanyang Central Hospital, Nanyang, Henan, China|Nanyang First People's Hospital, Nanyang, Henan, China|Puyang Oilfield General Hospital, Puyang, Henan, China|Xinxiang First People's Hospital, Xinxiang, Henan, China|Henan Cancer Hospital, Zhengzhou, Henan, China|Henan Provincial People's Hospital, Zhengzhou, Henan, China|The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China|Hubei Cancer Hospital, Wuhan, Hubei, China|Tongji Medical College of HUST, Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China|Wuhan Fifth Hospital, Wuhan, Hubei, China|Wuhan Union Hospital, Wuhan, Hubei, China|Hunan Cancer Hospital, Changsha, Hunan, China|Changzhou Tumor Hospital, Changzhou, Jiangsu, China|Huai'an First People's Hospital, Huai'an, Jiangsu, China|Jiangsu Province Hospital, Nanjing, Jiangsu, China|Jiangxi Cancer Hospital, Nanchang, Jiangxi, China|The First Affiliated Hospital Of Nanchang University, Nanchang, Jiangxi, China|Jilin Cancer Hospital, Changchun, Jilin, China|The Second Hospital of Jilin University, Changchun, Jilin, China|Tonghua Central Hospital, Tonghua, Jilin, China|Liaoning Cancer Hospital and Institute, Shenyang, Liaoning, China|Jinan central Hospital, Jinan, Shandong, China|Shandong Cancer Hospital, Jinan, Shandong, China|Linyi Cancer Hospital, Linyi, Shandong, China|The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China|Shanghai East Hospital, Shanghai, Shanghai, 201203, China|Shanghai Chest Hospital, Shanghai, Shanghai, China|Linfen Central Hospital, Linfen, Shanxi, China|Shanxi Provincial Cancer Hospital, Taiyuan, Shanxi, China|Chengdu Fifith people's hospital, Chengdu, Sichuan, China|Sichuan Provincial People's Hospital, Chengdu, Sichuan, China|West China Hospital Sichuan University, Chengdu, Sichuan, China|The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China|Suining Central Hospital, Suining, Sichuan, China|Yibin Second People's Hospital, Yibin, Sichuan, China|Tianjin Cancer Hospital, Tianjin, Tianjin, China|Tianjin Medical University General Hospital, Tianjin, Tianjin, China|Cancer Hospital Affiliated to Xinjiang Medical University, Urumqi, Xinjiang, China|Yunnan Cancer Hospital, Kunming, Yunnan, China|The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, China|Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China|Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China",
